Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …

Malaria remains a significant contributor to the global burden of disease, with around 40% of
the world's population at risk of Plasmodium infections. The development of an effective …

Background Development of an effective vaccine against the pathogenic blood-stage
infection of human malaria has proved challenging, and no candidate vaccine has affected …

Plants deploy receptor-like kinases and nucleotide-binding leucine-rich repeat receptors to
confer host plant resistance (HPR) to herbivores. These gene-for-gene interactions between …

The most severe form of malaria is caused by Plasmodium falciparum. These parasites
invade human erythrocytes, and an essential step in this process involves the ligand PfRh5 …

The symptoms of malaria occur during the blood stage of infection, when parasites invade
and replicate within human erythrocytes. The PfPCRCR complex, containing PfRH5 (refs.,) …

Malaria is a vector-borne disease of global importance, with the vast majority of its life-
threatening cases caused by infection with Plasmodium falciparum parasites. Repeated …

Understanding mechanisms of antibody synergy is important for vaccine design and
antibody cocktail development. Examples of synergy between antibodies are well …

Modifications to vaccine delivery that increase serum antibody longevity are of great interest
for maximizing efficacy. We have previously shown that a delayed fractional (DFx) dosing …

Reticulocyte-binding protein homologue 5 (RH5), a leading blood-stage Plasmodium
falciparum malaria vaccine target, interacts with cysteine-rich protective antigen (CyRPA) …